Natacha Lenuzza, Xavier Duval, Grégory Nicolas, Etienne Thévenot, Sylvie Job, Orianne Videau, Céline Narjoz, Marie-Anne Loriot, Philippe Beaune, Laurent Becquemont, France Mentré, Christian Funck-Brentano, Loubna Alavoine, Philippe Arnaud, Marcel Delaforge, Henri Bénech
This phase I, pilot clinical study was designed to evaluate the safety and the pharmacokinetic (PK) profiles of the CIME (Metabolic Identity Card) combination of ten drugs, with a view to its use as a phenotyping cocktail. Ten healthy Caucasian subjects were orally dosed with the CIME combination (caffeine-CYP1A2, repaglinide-CYP2C8, tolbutamide-CYP2C9, omeprazole-CYP2C19, dextromethorphan-CYP2D6, midazolam-CYP3A, acetaminophen-UGT1A1, 6&9 and 2B15, digoxin-P-gp, rosuvastatin-OATP1B1&3 and memantine-active renal transport)...
April 2016: European Journal of Drug Metabolism and Pharmacokinetics